Epidemiologic studies have reported inconsistent results regarding an association between 23
Introduction 36
An association between idiopathic Parkinson disease (PD), neuropathologically 37 characterized by the degeneration of pigmented dopaminergic neurons, and cutaneous 38 melanoma (melanoma), a cancer of pigment-producing melanocytes, was first reported in 39 1972. 1 This association was hypothesized to result from the chronic systemic administration of 40 levodopa (L-DOPA) -an intermediate in the dopamine synthesis pathway 2for the treatment of 41 PD 1,3 as L-DOPA is also a biosynthetic intermediate in the production of melanin. 2 Since that 42 time, several epidemiologic studies have examined the association between PD and melanoma 43 as well as other cancers. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The majority of studies have found that individuals with PD appear 44 to have a lower incidence of most cancers, with the exception of melanoma. 4, 5, 10, 12, 13, 15, 16 Both 45 prospective and retrospective studies have also found an increased risk of melanoma in PD that 46 appears to be independent of L-DOPA treatment. 4, 6, 7, 9, 15 This increased risk has been observed 47 to extend to family members and be reciprocal in nature with individuals being at greater risk for 48 PD if their relatives have a melanoma diagnosis and vice versa. 6,9 However, not all studies have 49 identified an association between melanoma and PD in affected individuals 12, 17 or their 50 relatives. 15 An epidemiologic association between lighter hair color and PD, a potentially shared 51 risk factor with melanoma, 18 has also been inconsistently reported. 17, 19 Epidemiologic 52 association studies are not without biases. PD is known to have an extended prodromal period 53 and a melanoma diagnosis necessitates longitudinal follow up, both of which increase medical 54 surveillance and thus the chance for spurious epidemiologic associations. 12, 20 In contrast, 55 studies of genetic variants associated with disease or cross-disease risk are not expected to be 56 influenced by usage of medical care, though they may be subject to similar misclassification 21 57 and ascertainment biases. 58
The first investigations of a genetic relationship between melanoma and PD focused on 59 variants in MC1R, a gene strongly associated with pigmentation and melanoma risk. 22 While 60 early reports identified an association between PD and MC1R variants 19, 23 other studies failed to 61 replicate these findings. [24] [25] [26] [27] Analyses focused on single variants in other melanoma risk genes 62
have also failed to yield consistent associations with PD. 17, 26, 28 Multi-variant analyses have thus 63 far reported a lack of genetic association as well. For example, a melanoma genetic risk score -64 calculated by aggregating the effect of melanoma genome-wide association study (GWAS)-65 significant (P < 5 × 10 -8 ) loci included in the GWAS catalog 29 as of 2012was not significantly 66 associated with PD. 30 Similarly, no evidence for an association between GWAS-significant 67 melanoma loci and PD is observed in a more recent multi-variant, Mendelian randomization 68 study. 31 In contrast, genes associated with Mendelian forms of PD have been identified to be 69 somatically mutated in melanoma lesions. [32] [33] [34] There may also exist an enrichment of Mendelian 70 PD gene germline variants in individuals with melanoma, 32 though this requires replication. 71
Nevertheless, over 90% of individuals with PD do not have mutations in any known Mendelian 72 PD genes. 35 Thus, variants in Mendelian PD genes are unlikely to fully explain any genetic 73 correlation between melanoma and PD. 74
The genetic risk architecture underlying complex diseases like PD and melanoma is 75 mediated by many common genetic variants of small effect size, most of which do not 76 demonstrate GWAS-significant associations given current study sample sizes. 36 Analyses which 77 only include GWAS-significant loci are not expected to fully represent the genetic architecture of 78 these complex diseases and thus may lead to false negative genetic overlap results. Recently, 79 statistical methods that aggregate all associated loci from disease-specific GWAS summary 80 statistic datasets in a linkage disequilibrium (LD)-informed manner have been developed to 81 better model these polygenic architectures. 37 These aggregated signals can be leveraged to 82 estimate the genetic correlation between different diseases, 37,38 even at the level of gene 83 expression in specific tissues 39, 40 or across tissues. 41 Here, we apply these novel methods to 84 GWAS summary statistics derived from the largest currently available studies of melanoma, 22 85 PD, [42] [43] [44] 
Meta-analyzing PD GWAS datasets 152
We used METAL software 48 to perform an inverse-variance weighted meta-analysis of 153 the three independent PD GWAS summary statistics. We refer to this meta-analyzed PD 154 dataset in the text, tables, and figures as METAPD (49,731 cases and 784,343 controls). 155 156
Standardization and Filtering of GWAS Summary Statistics 157
We standardized all summary statistics prior to polygenic analyses. We first confirmed 158 the genome build to be GRCh37, and then annotated variants with dbSNP v151 rs-identifiers 159 and gnomAD 49 non-Finnish European (NFE) allele frequencies using ANNOVAR software 160 (2018Apr16) 50 . We only included bi-allelic variants with rs-identifiers and in instances where 161 multiple variants shared the same rs-identifiers, we selected the variant that was supported by 162 the largest number of studies and/or the greatest sample size. Finally, we processed and filtered 163 summary statistics using the munge_sumstats.py tool provided with LD Score Regression 164 Software (LDSC) 37 . This processing and filtering removed variants with an effect allele 165 frequency of less than 0.05 in the gnomAD NFE population, variants with strand-ambiguous 166 alleles, variants supported by a low sample size or effective sample (Neff = 4/(1/Ncases+1/Ncontrols)) 167
for the meta-analysis, 48 and variants that were not reported in the HapMap3 study. 51 The 168 number of variants overlapping across all processed GWAS summary statistic datasets 169 analyzed in the present study are presented in Table 1 . 170 171
Estimating Genetic Overlap by GNOVA 172
We calculated genetic overlap using GNOVA software 38 . In brief, GNOVA calculates an 173 estimate of genetic covariance between two sets of GWAS summary statistics and further 174
provides an estimate of genetic correlation based on this calculated genetic covariance and the 175 estimated GWAS variant-based heritabilities. As with LD score regression 37 , GNOVA is able to 176 statistically correct for any sample overlap between two different sets of GWAS summary 177 statistics. In addition, GNOVA produces unbounded genetic correlation estimates which may be 178 greater than one for traits which are highly genetically correlated. GNOVA provides greater 179 statistical power and higher estimation accuracy for genetic correlations than LD score 180 regression, especially when the correlations are moderate, 38 as is expected for melanoma and 181 PD. We ran GNOVA software on the processed GWAS summary statistics using default 182 parameters and the 1000 Genomes 52 European population-derived reference data provided with 183 the software. Given we test the genetic correlation of melanoma against PD, AD, and FTD we 184 use a Bonferroni corrected significance threshold of P < 1.67 × 10 -02 (0.05 / 3). In the text we 185 present genetic correlations, 95% confidence intervals, and p-values that have been corrected 186 for sample overlap by GNOVA. 187 188 189
Disease-Inferred Gene Expression Overlap Analyses 190
We investigated whether the genetic overlap between PD and melanoma was mediated 191 by shared regulation of gene expression. To do this we generated tissue-specific, disease-192 inferred gene expression profiles from the processed GWAS summary statistics using 193 two traits that can be attributed to eQTLs as represented by the different trait-inferred gene 203 expression profiles. We exclude the major histocompatibility complex (MHC) region from 204 disease-inferred gene expression overlap analyses due to its complex LD structure. 39, 40 To 205 consider an overlap as significant we used a Bonferroni corrected threshold: P < 1.04 × 10 -03 206 (0.05 / 48) and present uncorrected p-values and 95% confidence intervals in the text. 207 208
Highlighting Genes Underlying Disease-Inferred Gene Expression Overlap 209
We used UTMOST software 41 to generate single-tissue, disease-inferred gene 210 expression, and then aggregated them into a summary metric representing cross-tissue, 211 eGene-disease associations. eGenes are those genes whose expression are influenced by a 212 least one cis disease-associated genetic variant. 54 For this analysis, we generated the single 213 tissue disease-inferred results based on the processed GWAS summary statistics and the 44 214 tissue GTEx v6 reference panel provided with UTMOST, using default parameters. We similarly 215 generated the cross-tissue summary metric using default parameters. The summary metric 216 generated by UTMOST does not include any indicator of uncertainty. We identified 217 transcriptome-wide significant, cross-tissue, eGene-disease associations using a false 218 discovery rate (FDR) threshold of 0.05, that is five expected false discoveries per 100 reported. 219
We compared PD and melanoma UTMOST summary metric eGene results for the disease-220 specific GWAS summary statistics to identify eGenes whose expression was similarly regulated 221 by different disease-associated variants. 222
223
Results 224
Polygenic Analysis Reveals Specific Genetic Overlap between Melanoma and PD 225
Prior to cross-disease analyses, we first confirmed that the three independent PD 226 datasets demonstrated positive and significant genetic correlation (genetic correlation range: 227 0.94 to 1.07, Table 2 ) using GNOVA software. Following this confirmation and method 228 validation, we proceeded to analyze for potential genetic correlations between melanoma, PD, 229 and the comparator neurodegenerative disease datasets. 230
We identified a significant and positive genetic correlation between melanoma and the 231 meta-analyzed PD dataset (genetic correlation: 0.17, 95% CI 0.10 to 0.24; P = 4.09 × 10 -06 , 232 Table 3 ). This result was not driven by any specific PD dataset, but all three independent 233 datasets contributed to the association (P < 0.05; genetic correlation range: 0.14 to 0.25, Figure  234 1 and Table 4 ). We found no shared genetic architecture between melanoma and Alzheimer 235 disease (genetic correlation: -0.02, 95% CI -0.11 to 0.07; P = 0.73, Table 3 ) nor between 236 melanoma and Frontotemporal dementia (genetic correlation: -0.13, 95% CI -0.37 to 0.12; P = 237 0.32, Table 3 ). 238
We did not observe any significant correlation between the meta-analyzed PD dataset 239 and AD (Table 3) , although one of the individual PD studies showed nominal correlation with AD 240 (Nalls2014: genetic correlation: -0.22, 95% CI -0.22 to 0.00, P = 4.94 × 10 -02 ; Table 4 ). We did 241 identify a positive and significant genetic correlation between the meta-analyzed PD dataset and 242 FTD (genetic correlation: 0.27, 95% CI 0.07 to 0.47; P = 8.43 × 10 -03 , Table 3 ), but this 243 appeared to be primarily driven by one of the individual PD studies (Table 4) . 244
Together these results demonstrate a consistent, positive and significant genetic 245 correlation between melanoma and PD but not between melanoma and FTD or AD. 246
247

PD and Melanoma Disease-Inferred Gene Expression Overlaps Across Tissues 248
To investigate whether melanoma and PD-associated risk variants regulated the 249 expression of the same genes, we generated disease-inferred, tissue-specific gene expression 250 profiles from the processed melanoma and METAPD GWAS summary statistic datasets via 251 FUSION/TWAS software. 39 We further investigated for overlap between the different disease-252 inferred gene expression profiles using RHOGE software. 40 253
We identified a positive and significant overlap between the PD-and melanoma-inferred Table 5 ), but only a statistically significant overlap in the suprapubic, non-sun-260 exposed, skin tissue (disease-inferred gene expression correlation: 0.37, 95% CI 0.17 to 0.57; 261 P: 7.58 × 10 -04 ). Eleven additional tissues demonstrated positive and nominal ( Figure 2 and 262 Table 5 ) the PD-and melanoma-inferred gene expression overlap including spleen (disease-263 inferred gene expression correlation: 0.40, 95% CI 0.13 to 0.66; P: 5.49 × 10 -03 ), minor salivary 264 gland (disease-inferred gene expression correlation: 0.45, 95% CI 0.15 to 0.75; P: 7.49 × 10 -03 ), 265 heart atrial appendage (disease-inferred gene expression correlation: 0.31, 95% CI 0.09 to 0.54; 266 P: 8.27 × 10 -03 ) brain substantia nigra (disease-inferred gene expression correlation: 0.42, 95% 267 CI 0.14 to 0.71; P: 9.02 × 10 -03 ), and brain caudate nucleus (disease-inferred gene expression 268 correlation: 0.29, 95% CI 0.01 to 0.58; P: 4.89 × 10 -02 ). 269
To highlight genes whose expression was commonly regulated by PD and melanoma 270 risk variants, we generated cross-tissue, summary metric eGene-disease associations using 271 UTMOST 41 software. Applying UTMOST to the METAPD GWAS summary statistics, we 272 identified 606 eGenes significantly associated with PD ( Supplementary Table 1 ), including 273 genes in previously reported PD-associated loci 42,47 , such as MAPT (P: 1.28 × 10 -04 ). In the 274 melanoma dataset, we identified 168 significantly associated eGenes ( Supplementary Table 2 ) 275
including those reported in a previous TWAS study 55 , such as MAFF (P: 1.28 × 10 -12 ). 276
Comparing the two sets of cross-tissue summary metric results, we identify seven eGene-277 disease associations that were passed the FDR threshold for both PD and melanoma: 278 GPATCH8, MYO9A, PIEZO1, SOX6, TRAPPC2L, ZNF341, and ZNF778 ( Figure 3 and Table  279 6). Together, these results suggest that some component of the genetic correlation between 280 melanoma and PD may be mediated by the shared regulation of gene expression across 281 tissues. 282 283
Discussion 284
In this study, we have identified a positive and significant genetic correlation between 285 melanoma and PD by leveraging the largest available GWAS summary statistic datasets and 286 recent advances in polygenic complex trait modeling 37, 38 (Tables 3-4 ). Our results support the 287 findings of several epidemiologic studies of sharedindividual and familialrisk 4-16 between 288 the two diseases. We also demonstrate no evidence for shared genetic overlap between 289 melanoma and two negative comparison neurodegenerative diseases: AD and FTD (Table 3) , 290 suggesting specificity. and PD have focused specifically on GWAS-significant loci and thus can be expected to have 305 missed a substantial proportion of the genetic architecture 36 underlying these complex diseases. 306
Genetic correlation methods that consider linkage disequilibrium structure and incorporate all 307 associated common variants are better powered to detect genetic overlap, especially given 308 current GWAS sample sizes, as we demonstrate here for melanoma and PD. 309
The classification and ascertainment of participants was different between the three 310 independent PD datasets included in the present study, but they all demonstrate positive and 311 significant genetic overlap with each other (Table 2) . While this overlap does not guarantee 312 specificity of the represented genetic architecture 56 , the fact we observe all three independent 313 PD studies to demonstrate positive and significant genetic overlap with melanoma ( Figure 1 and 314 Table 4 ) bolsters confidence in our results. Importantly, although the PD and melanoma genetic 315 correlation point estimates for the three individual PD studies appear different, their 95% 316 confidence intervals overlap which indicates that the effect size estimates are not significantly 317 different ( Figure 1 and Table 4 ). The genetic overlap between the independent PD datasets 318 supported their meta-analysis, and the genetic correlation between the meta-analyzed PD 319 dataset and melanoma provided the most precise estimate (genetic correlation: 0.17, 95% CI 320 0.10 to 0.24; P = 4.09 × 10 -06 ; Figure 1 and Tables 3-4). Further increases in precision can be 321 expected from incorporating additional independent GWAS summary statistic datasets and thus 322 our analyses should be repeated as these become available for both melanoma and PD. 323
Similarly, our FTD genetic correlation results should be interpreted with caution as the current 324 sample size is at least one order of magnitude smaller than the other disease datasets. For 325 example, among the individual PD datasets, we only observe a positive genetic correlation 326 between FTD and Nalls2019. Parkinsonism has been observed in about 20% on individuals with 327 FTD 57,58 , and this result may suggest that individuals with FTD with parkinsonism were included 328 among the UKB-proxy cases in the Nalls2019 dataset. Alternatively, a positive genetic 329 correlation between FTD and the other PD datasets may be observed from the use of a larger 330 FTD GWAS summary statistic dataset. Thus, our analyses should be repeated as larger GWAS 331 summary statistic datasets become available. 332
We infer disease-associated gene expression profiles 39 using melanoma and meta-333 analyzed PD GWAS summary statistics and investigate for their overlap at the level of tissues 40 334 and genes 41 to provide bioinformatically-driven biological context to our melanoma and PD 335 genetic correlation results. We identify significant cross-tissue overlap (disease-inferred gene 336 expression correlation: 0.14, 95% CI 0.06 to 0.22; P: 7.87 × 10 -04 ) and significant individual 337 tissue overlap in suprapubic non-sun-exposed skin (disease-inferred gene expression 338 correlation: 0.37, 95% CI 0.17 to 0.57; P: 7.58 × 10 -04 ). We also observe positive, nominal 339 disease-inferred gene expression correlation in peripheral tissues with PD relevance like the 340 heart atrial appendage (disease-inferred gene expression correlation: 0.31, P < 0.05, Table 5 ) -341 which may reflect the cardiac sympathetic denervation associated with PD 59,60 -or the minor 342 salivary glands (disease-inferred gene expression correlation: 0.45, P < 0.05, Table 5 ) -which 343 have been reported in some, but not all, studies as containing alpha synuclein aggregates in the 344 context of PD 61, 62 . In terms of PD-relevant brain tissues, we observe positive, nominal disease-345 inferred gene expression correlation in the substantia nigra and basal ganglia caudate nucleus 346 (disease-inferred gene expression correlation: 0.42 and 0.29, respectively; P < 0.05, Figure 2  347 and Table 5 ). Importantly, the available GTEx v7 inferred gene expression reference model for 348 brain tissues are based on substantially fewer samples than most peripheral tissues, for 349 example the brain substantia nigra reference is derived from 80 donors compared to 335 donors 350 for the suprapubic skin reference (Table 5) 
. Thus, our disease-inferred gene expression risk 351
profile overlap analyses should be repeated as larger reference panels become available. 352
We identify seven cross-tissue, eGene-disease associations passing the FDR threshold 353 for both melanoma and PD (Figure 3 and Table 6 ). Importantly, the UTMOST software currently 354 only provides a compatible reference panel based on the GTEx v6 release which is derived from 355 fewer donor samples per tissue compared to GTEx v7 release. In addition, the GTEx v6 356 reference panel does not include four tissues -brain substantia nigra, brain spinal cervical 357 spinal cord, brain amygdala, and minor salivary gland -which we observed to demonstrate 358 positive disease-inferred gene expression overlap for melanoma and PD (Table 5 ). Additional 359 eGenes may pass the FDR threshold for both PD and melanoma in analyses based on the 360 larger GTEx v7 reference panel. Thus, our analyses should be repeated when this or other 361 larger reference panels become available for UTMOST. Nevertheless, using the smaller GTEx 362 v6 reference panel we identify seven genes that may be commonly regulated by melanoma and 363 PD-associated variants under the FDR threshold ( Figure 3 and Table 6 ), including PIEZO1 364 (Melanoma P: 2.74 × 10 -11 ; METAPD P: 5.65 × 10 -05 ); TRAPPC2L (Melanoma P: 2.36 × 10 -11 ; 365 METAPD P: 8.47 × 10 -05 ); and SOX6 (Melanoma P: 1.30 × 10 -04 ; METAPD P: 5.97 × 10 -05 ). rhabdomyolysis. 75 The intergenic variant rs12921479 -which is an eQTL for TRAPPC2L in the 379 brain 53,76was reported to be associated with PD (P: 9.31 × 10 -07 ) in an autopsy-confirmed 380 cohort of PD 77 , but is only nominally associated with PD in our meta-analyzed PD dataset (P: 381 1.01 × 10 -02 ). 382 SOX6 is a transcription factor which was recently identified as a determinant of 383 substantia nigra neuron development and maintenance. 78 Its expression was observed to 384 localize to pigmented and tyrosine hydroxylase positive neurons but not to pigment-negative 385 neurons within the substantia nigra. 78 In addition, SOX6 expression was diminished in the 386 substantia nigra of individuals with PD and deletion of SOX6 in mice was observed to decrease 387 dopamine levels and innervation in the striatum, 78 a brain region that is also impacted in PD. 79 In 388 a separate study, a large deletion in SOX6 was identified in a patient with global developmental 389 delay and progressive parkinsonian symptoms including rest tremor. 80 Together, these findings 390 suggest a biologically plausible role for PIEZO1, TRAPPCL2, and SOX6 in the genetic 391 correlation between melanoma and PD, but these findings require confirmation and further 392 investigation with future experimental work. 393 PD and melanoma are clinically heterogenous diseases 81,82 for which spatiotemporal 394 environmental exposures are relevant 82,83 and may be necessary, in addition to innate genetic 395 susceptibility, for the development of sporadic disease. Consequently, the moderate genetic 396 correlation we observe should not be interpreted as suggesting that these diseases will always 397 be co-morbid. However, our results of replicable and significant genetic correlation, regardless 398 of the magnitude of effect, do suggest that these two very different diseases share common 399 biological pathways. Thus, even if only a minority of individuals with PD ultimately develop 400 melanoma, understanding the genetic correlation between these disease at the molecular level 401 for example, if and how the regulation of PIEZO1, TRAPPC2L, and SOX6 and their related 402 biological pathways contribute to PD etiopathogenesismay provide mechanistic insight that is 403 generalizable to all individuals with PD. Our results support such future research efforts. 404
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Parkinson disease summary statistic datasets. The red dashed line demarks the multiple test 791 We estimated the genetic correlation between the independent Parkinson disease datasets using 819 GNOVA software. All correlation estimates, 95% confidence intervalspresented in square 820
brackets -and p-values -presented in parentheses -are corrected for any potential sample 821
overlap. GNOVA genetic correlation estimates are unbounded and thus may be greater than 1.
822
METAPD is an inverse-variance-weighted meta-analysis of the three independent Parkinson 823 disease summary statistic datasets. 824 825 826 827 We estimated the genetic correlation between diseases using processed disease-specific GWAS 841 summary statistic datasets and GNOVA software. All correlation estimates, 95% confidence 842
intervalspresented in square bracketsand p-values -presented in parentheses -are corrected 843
for any potential sample overlap. PD: Parkinson disease; AD: Alzheimer disease; FTD: 844
Frontotemporal dementia. 845 846 We generated disease-inferred gene expression profiles based on standardized and processed 849 GWAS summary statistics using FUSION/TWAS software and the Genotype-Tissue Expression 850
Project (GTEx) v7 reference panel. We further compared the overlap of these disease-inferred 851 gene expression profiles using RHOGE software. METAPD is an inverse-variance-weighted 852 meta-analysis of the three independent Parkinson disease summary statistic datasets. PD: 853
Parkinson disease; ρGE: correlation coefficient for inferred transcriptomic overlap; BA: Brodmann 854
Area. 855 856 We inferred cross-tissue, eGene-disease associations based on standardized and processed 858 melanoma and METAPD GWAS summary statistics using UTMOST software and the 859
Genotype-Tissue Expression Project (GTEx) v6 reference panel. METAPD is an inverse-860
variance-weighted meta-analysis of the three independent Parkinson disease (PD) summary 861 statistic datasets. 862
